Table 2.
European guidelines on the spectrum of antifracture efficacy of pharmacological interventions for osteoporosis (*posthoc analysis in a subset of patients).
| Intervention | Vertebral | Non-vertebral | Hip |
|---|---|---|---|
| Alendronate | + | + | + |
| Risedronate | + | + | + |
| Zoledronic acid | + | + | + |
| Etidronate | + | - | - |
| Ibandronate | + | +* | - |
| Raloxifene | + | - | - |
| Strontium | + | + | +* |
| Teriparatide | + | + | - |
| Denosumab | + | + | + |